Expert perspectives on recent evolutions with CDK4/6 inhibitors in the HR+, HER2- metastatic breast cancer treatment landscape.
July 20th 2022
Considerations for how novel antibody drug conjugates (ADCs) and selective androgen receptor modulators (SARMs) may respectively address mechanisms of resistance within HR+/HER2- metastatic breast cancer.
Broad perspectives on various novel mechanisms of action that may address acquired resistance to therapies for HR+/HER2- metastatic breast cancer.
July 27th 2022
Before closing out their discussion on CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, experts highlight remaining unmet needs in this setting.
Key opinion leaders in breast cancer management share their excitement for data that will be released at the annual ASCO meeting in 2022 or the near future.